GlobeNewswire by notified

Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

Share
  • Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms1

  • Safety results were consistent with the well-established Cosentyx safety profile

  • HS is a chronic, inflammatory skin condition affecting up to one in 100 people worldwide2, resulting in painful, potentially disfiguring lesions, which leaves feelings of stigmatization and can severely impact quality of life3,4

  • Data from SUNSHINE and SUNRISE trials were submitted as part of regulatory applications to health authorities in Europe; plan to submit in the US by year end

Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile5,6. The data were presented as a late-breaking abstract at the 31st European Academy of Dermatology and Venereology (EADV) Congress1.

“Hidradenitis suppurativa can cause intense pain, disability and anxiety, impacting many aspects of daily living. However, there are only limited treatment options available that can make a difference to people living with this debilitating disease,” said Dr. Alexa B. Kimball, lead investigator of the trials, investigator at Beth Israel Deaconess Medical Center, and Professor of Dermatology, Harvard Medical School. “These efficacy and safety findings are promising for people living with HS, who are in urgent need of new treatment options.”

These Phase III data have been submitted to regulatory authorities in Europe and will be submitted to regulatory authorities in the United States this year, with the goal of bringing Cosentyx as a new treatment option to patients living with HS as soon as possible.
Novartis also plans to share the long-term results from the trials in 2023. Available data support the sustained efficacy over continuous treatment up to 52 weeks in patients with HS7.

“We are excited to share these promising results showing the benefit of Cosentyx as a treatment that provides relief from common signs and symptoms, pain and flares for people living with HS, with a favorable safety profile. We hope to offer Cosentyx as a potential new treatment option as soon as possible to support this underserved patient community, as part of our ambition to expand Cosentyx to 10 indications,” said Todd Fox, Global Head of Medical Affairs Immunology, Novartis. “Beyond Cosentyx, we are also committed to advancing research in HS and are currently exploring a number of treatments with various mechanisms of action with hopes to further address the ongoing unmet needs of people living with this disease.”

The trials assessed two Cosentyx dose regimens across 16-week (vs placebo) and 52-week treatment periods. Results showed a significantly higher proportion of patients achieved a Hidradenitis Suppurativa Clinical Response (HiSCR) when treated with Cosentyx 300 mg, dosed every two weeks (after standard weekly loading doses), compared with placebo at Week 16 in both the SUNSHINE and SUNRISE trials (45.0% vs 33.7% [P=.0070] and 42.3% vs 31.2% [P=0.0149], respectively)1. Cosentyx 300 mg dosed every four weeks (after standard weekly loading doses) was superior to placebo for achieving HiSCR in the SUNRISE study (46.1% vs 31.2% [P=0.0022]), though did not meet statistical significance in the SUNSHINE study (41.8% vs 33.7% [P=0.0418])5,6. HiSCR is defined as at least a 50% decrease in abscess and inflammatory nodule count with no increase in the number of abscesses and/or draining tunnels5,6. The safety profile was consistent with that of Cosentyx in existing indications, and no new safety signals were observed in either dosing group1.

A key secondary endpoint was skin pain, as measured by the patient’s global assessment of skin pain Numeric Rating Scale (NRS30). In data pooled from the two studies, the 300 mg dose of Cosentyx given every two weeks proved statistically superior to placebo in reducing skin pain, the most bothersome symptom of HS1,8. Further details on the primary and secondary endpoints are available on the Novartis website: https://www.novartis.com/healthcare-professionals/medical-congresses-and-events/abstract-summaries-eadv.

Since its initial approval in 2015, Cosentyx has helped more than 700,000 patients worldwide across five approved immune-mediated diseases, with the goal of preventing disease progression across even more immunological conditions in the future while demonstrating sustained treatment efficacy and safety9-20.

About the SUNSHINE and SUNRISE trials
The SUNSHINE and SUNRISE trials comprise the largest Phase III program in hidradenitis suppurativa (HS), having enrolled more than 1,000 patients in 33 countries5,6. SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) are identical, global Phase III multicenter, randomized, double-blind, placebo-controlled, parallel group studies that evaluated the short- (16 weeks) and long-term (up to 52 weeks) efficacy, safety and tolerability of two dose regimens of Cosentyx in adults with moderate-to-severe HS. SUNSHINE included 541 patients, and SUNRISE included 543 patients. Patients in each study were randomized to one of three experimental arms: Cosentyx 300 mg every two weeks after five weekly loading doses; Cosentyx 300 mg every four weeks after five weekly loading doses; placebo dose every two weeks after five weekly placebo doses. The primary endpoint of both trials assessed achievement of HS Clinical Response (HiSCR) after 16 weeks of treatment. Key secondary endpoints included the percentage change from baseline in abscess and inflammatory nodule (AN) count at Week 16, proportion of patients experiencing a flare over 16 weeks, and proportion of patients with Numeric Rating Scale 30 (skin pain) response (reported as pooled data from both trials) at Week 16.

About Cosentyx® (secukinumab)
Cosentyx is the first and only fully human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis (PsA), moderate to severe plaque psoriasis, ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)16,21. Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including five years of clinical data in adults supporting long-term safety and efficacy across moderate to severe plaque psoriasis, PsA and AS9-15,22. These data strengthen the position of Cosentyx as a treatment across AS, nr-axSpA, PsA, moderate to severe plaque psoriasis (adult and pediatric) and two subtypes of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA). More than 700,000 patients have been treated with Cosentyx worldwide since launch in 201516,19,20. Cosentyx is approved in more than 100 countries, most recently gaining approval for JIA in the United States and Europe.

About hidradenitis suppurativa (HS)
HS is a chronic, inflammatory, debilitating skin condition with systemic comorbidities that has a profoundly negative effect on a patient’s quality of life and mental health2-4. It is characterized by recurrent lumps or nodules under the skin that become inflamed and painful, breaking open to cause abscesses and sores2,23. The chronic debilitating nature of HS makes it one of the most distressing dermatological conditions, with a considerable psychological burden on sufferers3. Once considered a rare condition, it is now thought that as many as one in 100 people are affected by HS2. There is no cure for HS and current HS treatment regimens are limited, often inadequate and can require a surgical approach24,25. Often, they cannot be taken for an extended time, or only provide temporary and moderate relief24,25. It takes on average seven years to get an HS diagnosis after the first onset of symptoms26.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References

1.    Kimball AB, Alavi A, Jemec GBE, et al. Secukinumab in moderate to severe hidradenitis suppurativa: Primary endpoint analysis from the SUNSHINE and SUNRISE Phase 3 trials. LB-3549. Presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress; September 7–10, 2022; Milan, Italy.
2.    MedLine Plus. Hidradenitis suppurativa [online]. Available from: https://medlineplus.gov/genetics/condition/hidradenitis-suppurativa/ [Last accessed: September 2022].
3.    Mac Mahon J, Kirthi S, Byrne N, et al. An Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa. Patient Relat Outcome Meas. 2020;11:21-26.
4.    Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6:18.
5.    ClinicalTrials.gov. Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) (SUNRISE). NCT03713632. Available from: https://clinicaltrials.gov/ct2/show/NCT03713632. [Last accessed: September 2022].
6.    ClinicalTrials.gov. This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). (SUNSHINE). NCT03713619. Available from: https://clinicaltrials.gov/ct2/show/NCT03713619. [Last accessed: September 2022].
7.    Novartis Data on file. SUNSHINE and SUNRISE trials. [Last accessed: September 2022].
8.    Montero-Vilchez T, Diaz-Calvillo P, Rodriguez-Pozo JA, et al. The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2021;18.
9.    Baraliakos X, Braun J, Deodhar A, et al. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019;5:e001005.
10.    Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32:1507-1514.
11.    Mease PJ, Kavanaugh A, Reimold A, et al. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020;2:18-25.
12.    McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137-46.
13.    Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.
14.    Data on file. CAIN457F2310 and CAIN457F2305 summary of 5-year clinical safety in (ankylosing spondylitis). Novartis Pharmaceuticals Corp; May 2019.
15.    Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals Corp; November 2008.
16.    Novartis Europharm Limited. Cosentyx® (secukinumab): Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf [Last accessed: September 2022].
17.    Ruperto N, Foeldvari I, Alexeeva E, et al. Efficacy and Safety of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Primary Results from a Randomised, Double-blind, Placebo-controlled, Treatment Withdrawal, Phase 3 Study (JUNIPERA). Presented as a late-breaking abstract at European Alliance of Associations For Rheumatology (EULAR) Virtual Congress; June 2-5, 2021. Abstract LB0004.
18.    Brunner H, Foeldvari I, Alexeeva E, et al. Secukinumab Treatment In Children And Adolescents with Enthesitis-Related Arthritis And Juvenile Psoriatic Arthritis: Efficacy And Safety Results From A Phase 3 Study. Presented at the American College of Rheumatology (ACR) Convergence; October 28-30, 2021. Abstract 1424.
19.    Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; December 2021.
20.    Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008.
21.    Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717-24.
22.    McInnes IB, Behrens F, Mease PJ, et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet. 2020;395:1496-1505.
23.    National Institute of Health (NIH) Genetic and Rare Diseases Information Center (GARD). Hidradenitis suppurativa [online]. Available from: https://rarediseases.info.nih.gov/diseases/6658/hidradenitis-suppurativa#ref_15130 [Last accessed: September 2022].
24.    Vinkel C and Thomsen SF. Hidradenitis Suppurativa: Causes, Features, and Current Treatments. J Clin Aesthet Dermatol. 2018;11:17-23.
25.    Gill L, Williams M and Hamzavi I. Update on hidradenitis suppurativa: connecting the tracts. F1000Prime Rep. 2014;6:112.
26.    Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173:1546-9.

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Michael Meo
Novartis US External Communications
+1 862 274 5414 (direct)
michael.meo@novartis.com



Julie Masow
Novartis US External Communications
+1 862 579 8456
julie.masow@novartis.com
Chandler Wright
Novartis Pharma Communications
+1 470 660 2365 (direct)
chandler.wright@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah+41 61 324 7944Sloan Simpson+1 862 345 4440
Nicole Zinsli-Somm+41 61 324 3809Alina Levchuk+1 862 778 3372
Isabella Zinck+41 61 324 7188Parag Mahanti+1 973 876 4912
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Inbjudan till HMS Networks telefonkonferens för det tredje kvartalet 202229.9.2022 11:30:00 CEST | Pressemelding

HMS Networks AB (publ) offentliggör sin rapport för det tredje kvartalet 2022 onsdagen den 19 oktober 2022 kl. 07.30. Samma dag kl. 09.00 arrangeras en telefonkonferens för press och aktiemarknad, där VD och koncernchef Staffan Dahlström samt finanschef Joakim Nideborn presenterar rapporten. Presentationen hålls på engelska och följs direkt via telefon eller via internet. De bilder som används under presentationen kommer att finnas tillgängliga på HMS webbplats före telefonkonferensen. För att delta i telefonkonferensen, ring in eller följ webbpresentationen via länken nedan. SE: +46 8 505 583 50 UK: +44 33 3300 9034 US: +1 646 722 4904 Länk till webbsändningen Presentation och inspelning av telefonkonferensen kommer sedan att finnas tillgängligt på HMS webbsida. https://www.hms-networks.com/sv/aktieagare För mer information, kontakta: Staffan Dahlström, VD HMS, +46 (0)35 17 29 01 Joakim Nideborn, Finanschef HMS, +46 (0)35 710 6983 HMS Networks AB (publ) är en marknadsledande leverantö

Invitation to HMS Networks’ third quarter 2022 conference call29.9.2022 11:30:00 CEST | Press release

HMS Networks AB (publ) will release its third quarter report 2022 on Wednesday October 19, 2022, at 07.30 CET. On the same day, at 09.00 CET, a conference call will be held for press and analysts, where President and CEO Staffan Dahlström and CFO Joakim Nideborn present the report. The presentation will be held in English and is followed live by telephone or the internet. Slides used in the presentation will be made available on HMS’ website prior to the telephone conference. To participate in the telephone conference, please call or follow the online presentation via the link below. SE: +46 8 505 583 50 UK: +44 33 3300 9034 US: +1 646 722 4904 Link to webcast The presentation and recording of the telephone conference will be available on HMS’ website after the call. https://www.hms-networks.com/ir For more information, please contact: Staffan Dahlström, CEO HMS, +46 (0)35 17 29 01 Joakim Nideborn, CFO HMS, +46 (0)35 710 6983 HMS Networks AB (publ) is a market-leading provider of solut

Eidosmedia partners with Sophi.io on AI-powered print automation29.9.2022 10:00:00 CEST | Press release

The partnership integrates Sophi.io’s AI technology into Eidosmedia’s editorial platform, bringing seamless ML-powered print laydown automation to Eidosmedia customers TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Eidosmedia, a developer of digital publishing solutions for leading news-media groups worldwide, has partnered with Sophi.io, an AI-powered automation, optimization and prediction platform developed by The Globe and Mail, to bring seamless print laydown automation to Eidosmedia customers. The solution brings the entire print page layout process down from hours to just minutes, without the use of templates. Publishers can dramatically improve productivity and cut costs, all within the Méthode platform they currently use. “The complexity of print page layouts has until now defied the easy automation that speeds the publishing of online formats,” said Marco Cetola, Eidosmedia Sales and Partner Program Director. “For our customers, especially large regional groups and national titl

Hypefactors project backed by Innovation Fund Denmark29.9.2022 09:54:19 CEST | Press release

Copenhagen, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Announcement no. 10-2022 Inside Information It is announced that Innovation Fund Denmark, from its Innobooster program, has granted Hypefactors DKK 988,575 to support development of the project 'New Print PDF Processing Program', in where we will develop and roll-out an advanced automated solution for processing of printed news (from newspapers and magazines). In the project, we aim to apply recent scientific breakthroughs in computational linguistics (NLP) combined with AI-techniques beyond machine learning: Automated reasoning engine and probabilistic programming. The 'New Print PDF Processing Program' will enable us to deliver a magnitude larger print coverage than any competitor​ and to​ deliver a superior solution to large enterprises with cross-border media presence. The project will kick off in October 2022 and is expected to be finalized within a period of 10 months. CEO Casper Janns: “Our dedicated ambition is to develop and deliv

Preliminary results of the recommended voluntary exchange offer for all shares in Magseis Fairfield ASA29.9.2022 08:30:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, INTO OR WITHIN AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Oslo, Norway (29 September 2022) - Reference is made to the stock exchange announcement on 29 June 2022 regarding the recommended voluntary exchange offer (the "Offer") by TGS ASA ("TGS" or the "Offeror", OSE: TGS) to acquire all shares in Magseis Fairfield ASA ("Magseis Fairfield" OSE: MSEIS) and to the stock exchange announcement on 24 August 2022 regarding the formal launch of the Offer. Reference is also made to the offer document for the Offer dated 24 August 2022 (the "Offer Document"), and to the stock exchange announcements on 21 September 2022 regarding the extension of the offer period until 28 September 2022, on 22 September 2022 regarding the update on acceptances, and on 23 September 2022 regarding amendment of the minimu